Multiple EUAs granted for large trials demonstrati

Multiple EUAs granted for large trials demonstrating small effect. Significant p values obtained with sufficient trial size.

Neutralizing antibodies, remdesivir, tocilizumab.

There is, unfortunately, no moving past the fact that the spectacular CD12 results were at 14 days/halfway point, in 62 patients/16% of total trial size.

Believing wholeheartedly in the leronlimab, its MOA, and the importance of these results, its only matter of time until leronlimab has its day in severe covid.

Covid will still be with us in January 2022. It's the nature of the regulatory process that EUA and approval granted on certainty of results, even if a small impact (witnessing remdesivir and putting aside the recent Adhelm decision).

Water under the bridge, but had Cytodyn conducted a trial with remdesivir with 2,000 patients, Leronlimab would now be the SOC.

1000 severe, 300 critical in upcoming Brazilian trials should suffice. I have substantially more confidence in Albert Einstein than a repeat with Amarex.